Send to

Choose Destination
World J Nephrol. 2015 Feb 6;4(1):83-91. doi: 10.5527/wjn.v4.i1.83.

Lipid abnormalities in kidney disease and management strategies.

Author information

Vishwam Pandya, Akhilesh Rao, Kunal Chaudhary, Division of Nephrology, University of Missouri Health Science Center, Columbia, MO 65212, United States.


Patients with kidney diseases continue to experience significant cardiovascular disease (CVD) morbidity and mortality. Although there are many important risk factors playing a role in the pathogenesis of CVD in chronic kidney disease (CKD) patients, dyslipidemia (elevated triglycerides, elevated oxidized low-density lipoprotein and low/dysfunctional low high-density) represents one of the modifiable risk factors. Renal failure patients have unique lipid abnormalities which not only have complex role in pathogenesis of CVD but also cause relative resistance to usual interventions. Most of the randomized trials have been in hemodialysis population and data from CKD non-dialysis, peritoneal dialysis and renal transplant populations is extremely limited. Compared to general population, evidence of mortality benefit of lipid lowering medications in CKD population is scarce. Future research should be directed towards establishing long term benefits and side effects of lipid lowering medications, through randomized trials, in CKD population.


Cardiovascular disease; Chronic kidney disease; Dyslipidemia; Hemodialysis; Peritoneal dialysis; Renal transplant recipients; Statins

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center